179 related articles for article (PubMed ID: 24929675)
21. Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer.
Li C; Wang B; Lu D; Jin JY; Gao Y; Matsunaga K; Igawa Y; Nijem I; Lu M; Strasak A; Chernyukhin N; Girish S
Cancer Chemother Pharmacol; 2016 Sep; 78(3):547-58. PubMed ID: 27423671
[TBL] [Abstract][Full Text] [Related]
22. Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1).
Uppal H; Doudement E; Mahapatra K; Darbonne WC; Bumbaca D; Shen BQ; Du X; Saad O; Bowles K; Olsen S; Lewis Phillips GD; Hartley D; Sliwkowski MX; Girish S; Dambach D; Ramakrishnan V
Clin Cancer Res; 2015 Jan; 21(1):123-33. PubMed ID: 25370470
[TBL] [Abstract][Full Text] [Related]
23. Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer.
Wang J; Song P; Schrieber S; Liu Q; Xu Q; Blumenthal G; Amiri Kordestani L; Cortazar P; Ibrahim A; Justice R; Wang Y; Tang S; Booth B; Mehrotra N; Rahman A
Clin Pharmacol Ther; 2014 May; 95(5):558-64. PubMed ID: 24488143
[TBL] [Abstract][Full Text] [Related]
24. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
Med Lett Drugs Ther; 2013 Sep; 55(1425):75-6. PubMed ID: 24662957
[No Abstract] [Full Text] [Related]
25. Multiple spider telangiectasias in a breast cancer patient on T-DM1 treatment.
Ruiz-Rivero J; Horcajada-Reales C; Tardío JC; Borbujo-Martínez JM
An Bras Dermatol; 2018; 93(6):938-939. PubMed ID: 30484553
[No Abstract] [Full Text] [Related]
26. Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1).
Chung YC; Kuo JF; Wei WC; Chang KJ; Chao WT
PLoS One; 2015; 10(7):e0133072. PubMed ID: 26172389
[TBL] [Abstract][Full Text] [Related]
27. Ado-trastuzumab emtansine for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer.
Patel KC; Hageman K; Cooper MR
Am J Health Syst Pharm; 2014 Apr; 71(7):537-48. PubMed ID: 24644113
[TBL] [Abstract][Full Text] [Related]
28. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.
Beeram M; Krop IE; Burris HA; Girish SR; Yu W; Lu MW; Holden SN; Modi S
Cancer; 2012 Dec; 118(23):5733-40. PubMed ID: 22648179
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
Krop IE; Beeram M; Modi S; Jones SF; Holden SN; Yu W; Girish S; Tibbitts J; Yi JH; Sliwkowski MX; Jacobson F; Lutzker SG; Burris HA
J Clin Oncol; 2010 Jun; 28(16):2698-704. PubMed ID: 20421541
[TBL] [Abstract][Full Text] [Related]
30. Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report.
Miranda Romero P; Marín Gil R
Farm Hosp; 2015 May; 39(3):171-5. PubMed ID: 26005893
[TBL] [Abstract][Full Text] [Related]
31. Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability.
Poon KA; Flagella K; Beyer J; Tibbitts J; Kaur S; Saad O; Yi JH; Girish S; Dybdal N; Reynolds T
Toxicol Appl Pharmacol; 2013 Dec; 273(2):298-313. PubMed ID: 24035823
[TBL] [Abstract][Full Text] [Related]
32. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
Med Lett Drugs Ther; 2013 Sep; 55(1424):75-6. PubMed ID: 24043217
[No Abstract] [Full Text] [Related]
33. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.
Welslau M; Diéras V; Sohn JH; Hurvitz SA; Lalla D; Fang L; Althaus B; Guardino E; Miles D
Cancer; 2014 Mar; 120(5):642-51. PubMed ID: 24222194
[TBL] [Abstract][Full Text] [Related]
34. Telangiectasia and Pulmonary Arterial Hypertension Following Treatment With Trastuzumab Emtansine: A Case Report.
Kwon Y; Gomberg-Maitland M; Pritzker M; Thenappan T
Chest; 2016 Apr; 149(4):e103-5. PubMed ID: 27055712
[TBL] [Abstract][Full Text] [Related]
35. Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity.
Yan H; Endo Y; Shen Y; Rotstein D; Dokmanovic M; Mohan N; Mukhopadhyay P; Gao B; Pacher P; Wu WJ
Mol Cancer Ther; 2016 Mar; 15(3):480-90. PubMed ID: 26712117
[TBL] [Abstract][Full Text] [Related]
36. Ado-trastuzumab emtansine associated spider telangiectasia.
Gursoy P; Acar A; Acikalin T
J Oncol Pharm Pract; 2022 Jun; 28(4):986-988. PubMed ID: 35040682
[TBL] [Abstract][Full Text] [Related]
37. Trastuzumab emtansine: first global approval.
Ballantyne A; Dhillon S
Drugs; 2013 May; 73(7):755-65. PubMed ID: 23620199
[TBL] [Abstract][Full Text] [Related]
38. Ado-trastuzumab emtansine approved for advanced breast cancer.
Traynor K
Am J Health Syst Pharm; 2013 Apr; 70(7):562. PubMed ID: 23515502
[No Abstract] [Full Text] [Related]
39. Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
Gupta M; Lorusso PM; Wang B; Yi JH; Burris HA; Beeram M; Modi S; Chu YW; Agresta S; Klencke B; Joshi A; Girish S
J Clin Pharmacol; 2012 May; 52(5):691-703. PubMed ID: 21953571
[TBL] [Abstract][Full Text] [Related]
40. [A Case of Advanced Breast Cancer in Which Marked Improvement of Joint Pain Was Obtained with Stepwise Dose Reduction of Trastuzumab Emtansine (T-DM1)].
Yabe N; Murai S; Harada Y; Yokose T; Yokoe T; Oto I; Yoshikawa T; Kitasato K; Shimizu H; Jinno H; Kitagawa Y
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1818-20. PubMed ID: 26805183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
